News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

Teva Releases Q3 2026 Aide Memoire

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Teva Announces Launch of Offering of Senior Notes

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more

Media Kit

Files and resources for media use only
Download Teva Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more

Connect with us

Teva Social Media Guidelines.
Learn more